EMA Application withdrawn: Tyvaso (treprostinil sodium) — United Therapeutics Europe Ltd

View source ↗

Summary

EMA reports that the application for Tyvaso (treprostinil sodium) by United Therapeutics Europe Ltd has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Hypertension

Drugs mentioned

• Tyvaso (treprostinil)

Snippet

Status: Application withdrawn. Therapeutic area: Hypertension, Pulmonary. MAH: United Therapeutics Europe Ltd. Decision date: 26/04/2010. Orphan medicine